Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis Journal Article
| Authors: | Goel, U.; Dima, D.; Davis, J.; Ahmed, N.; Shaikh, H.; Lochner, J.; Abdallah, A. O.; Khouri, J.; Hashmi, H.; Anwer, F. |
| Article Title: | Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis |
| Abstract: | Clinical trials evaluating chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (RRMM) have typically excluded patients with AL amyloidosis. As a result, there are limited data on the safety and efficacy of CAR T-cell therapy in this patient population. We retrospectively reviewed eight consecutive patients with RRMM and AL amyloidosis who were treated with standard of care CAR T-cell therapy. Cytokine release syndrome was seen in 75% of patients (grade ≥3: 0%) and immune effector cell-associated neurotoxicity syndrome (grade 1) in only one patient. Low-grade cytopenias were common (any grade/grade ≥3: neutropenia 62.5%/37.5%, anemia 37.5%/0%, thrombocytopenia 25%/0%). CAR T-cell therapy led to rapid and deep responses with a median time to best response of 43 days and a hematologic very good partial response or better rate of 62.5%. Overall, we found that commercial CAR T-cell therapy was feasible, and effective in patients with RRMM and concurrent AL amyloidosis. © 2024 The Author(s). European Journal of Haematology published by John Wiley & Sons Ltd. |
| Keywords: | adult; clinical article; treatment outcome; treatment response; aged; middle aged; retrospective studies; fludarabine; thrombopoietin receptor; disease course; neutropenia; cancer recurrence; cisplatin; doxorubicin; drug efficacy; drug safety; cancer patient; neurotoxicity; bortezomib; proteasome inhibitor; multiple myeloma; anemia; etoposide; thrombocytopenia; cohort analysis; recurrence; bendamustine; cyclophosphamide; dexamethasone; amyloidosis; drug resistance; drug resistance, neoplasm; retrospective study; cancer resistance; health care quality; immunology; diagnosis; recurrent disease; chimeric antigen receptor; effector cell; immunomodulating agent; disease management; granulocyte colony stimulating factor; cytopenia; therapy; adoptive immunotherapy; immunotherapy, adoptive; viral respiratory tract infection; carfilzomib; etiology; adverse event; clinical outcome; cytokine release syndrome; procedures; colony stimulating factor; al amyloidosis; tocilizumab; humans; human; male; female; article; b cell maturation antigen; daratumumab; selinexor; b-cell maturation antigen; chimeric antigen receptor t-cell immunotherapy; car t-cell therapy; receptors, chimeric antigen; ciltacabtagene autoleucel; idecabtagene vicleucel; immunoglobulin light-chain amyloidosis |
| Journal Title: | European Journal of Haematology |
| Volume: | 113 |
| Issue: | 6 |
| ISSN: | 0902-4441 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2024-12-01 |
| Start Page: | 817 |
| End Page: | 823 |
| Language: | English |
| DOI: | 10.1111/ejh.14293 |
| PUBMED: | 39189919 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
